1. Home
  2. ABCL vs LBTYK Comparison

ABCL vs LBTYK Comparison

Compare ABCL & LBTYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$12.61

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Logo Liberty Global Ltd. Class C

LBTYK

Liberty Global Ltd. Class C

HOLD

Current Price

$9.85

Market Cap

3.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABCL
LBTYK
Founded
2012
2004
Country
Canada
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
ABCL
LBTYK
Price
$12.61
$9.85
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$8.40
N/A
AVG Volume (30 Days)
4.4M
1.5M
Earning Date
05-11-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
10.91
N/A
EPS
N/A
0.96
Revenue
$75,128,000.00
$11,541,500,000.00
Revenue This Year
N/A
$15.41
Revenue Next Year
$21.85
$3.03
P/E Ratio
N/A
$10.22
Revenue Growth
160.56
N/A
52 Week Low
$2.75
$9.30
52 Week High
$13.18
$13.12

Technical Indicators

Market Signals
Indicator
ABCL
LBTYK
Relative Strength Index (RSI) 65.97 39.28
Support Level $10.38 $9.30
Resistance Level N/A $10.67
Average True Range (ATR) 0.61 0.27
MACD -0.01 -0.07
Stochastic Oscillator 79.02 18.84

Price Performance

Historical Comparison
ABCL
LBTYK

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

About LBTYK Liberty Global Ltd. Class C

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: